Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of a Long-lasting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients With Advanced Metastatic Neuroendocrine Tumors
Brief Summary: This is a prospective study to investigate the long-lasting radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluate response to 177Lu-DOTA-EB-TATE in patients with advanced metastatic neuroendocrine tumors. Different groups with doses of 0.37GBq-0.74GBq (10-20 mCi) and 1.85GBq (50 mCi)of 177Lu-DOTA-EB-TATE, 3.7GBq (100 mCi)of 177Lu-DOTA-TATE will be injected intravenously. Besides, we evaluated the safety and dosimetry of 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE with and without amino acid infusion. All patients will undergo 68Ga-DOTATATE PET/CT scans before and after the treatment.


Options:
A: Arm Label: 250 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Arm Label: 500 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo-matching telotristat etiprate | Arm Label: Telotristat Etiprate Open-Label Extension; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Intervention Type: DRUG; Name: Telotristat etiprate; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate, Telotristat Etiprate Open-Label Extension | Intervention Type: DRUG; Name: Placebo-matching telotristat etiprate; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate, Placebo, Telotristat Etiprate Open-Label Extension
B: Arm Label: 177Lu-DOTA-EB-TATE 1; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 1 | Arm Label: 177Lu-DOTA-EB-TATE 2; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 2 | Arm Label: 177Lu-DOTA-EB-TATE 3; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 3 | Arm Label: 177Lu-DOTA-TATE; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-TATE | Arm Label: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine); Type: EXPERIMENTAL; Interventions: Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine) | Arm Label: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine); Type: EXPERIMENTAL; Interventions: Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine) | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 1; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 1 | Intervention Type: DRUG; Name: 177Lu-DOTA-TATE; Assigned to Arm(s): 177Lu-DOTA-TATE | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 2; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 2 | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 3; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 3 | Intervention Type: DRUG; Name: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine); Assigned to Arm(s): 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine) | Intervention Type: DRUG; Name: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine); Assigned to Arm(s): 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)
C: Arm Label: lanreotide; Type: EXPERIMENTAL; Interventions: Drug: lanreotide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lanreotide; Assigned to Arm(s): lanreotide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Octreotide+ Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Octreotide, Drug: Everolimus | Arm Label: Octreotide+ Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Octreotide, Drug: Placebo | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Octreotide+ Everolimus, Octreotide+ Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Octreotide+ Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Octreotide+ Everolimus

Answer: B